已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

医学 多西紫杉醇 内科学 肺癌 阿维鲁单抗 人口 肿瘤科 临床终点 临床试验 癌症 彭布罗利珠单抗 免疫疗法 环境卫生
作者
Fabrice Barlési,Johan Vansteenkiste,David R. Spigel,Hidenobu Ishii,Marina Chiara Garassino,Filippo de Marinis,Mustafa Özgüroğlu,Aleksandra Szczęsna,Andreas Polychronis,Rüçhan Uslu,Maciej Krzakowski,Jong Seok Lee,Luana Calabrò,Osvaldo Arén Frontera,Barbara Ellers‐Lenz,Marcis Bajars,Mary Ruisi,Keunchil Park
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (11): 1468-1479 被引量:397
标识
DOI:10.1016/s1470-2045(18)30673-9
摘要

Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.JAVELIN Lung 200 was a multicentre, open-label, randomised, phase 3 trial at 173 hospitals and cancer treatment centres in 31 countries. Eligible patients were aged 18 years or older and had stage IIIB or IV or recurrent NSCLC and disease progression after treatment with a platinum-containing doublet, an Eastern Cooperative Oncology Group performance status score of 0 or 1, an estimated life expectancy of more than 12 weeks, and adequate haematological, renal, and hepatic function. Participants were randomly assigned (1:1), via an interactive voice-response system with a stratified permuted block method with variable block length, to receive either avelumab 10 mg/kg every 2 weeks or docetaxel 75 mg/m2 every 3 weeks. Randomisation was stratified by PD-L1 expression (≥1% vs <1% of tumour cells), which was measured with the 73-10 assay, and histology (squamous vs non-squamous). The primary endpoint was overall survival, analysed when roughly 337 events (deaths) had occurred in the PD-L1-positive population. Efficacy was analysed in all PD-L1-positive patients (ie, PD-L1 expression in ≥1% of tumour cells) randomly assigned to study treatment (the primary analysis population) and then in all randomly assigned patients through a hierarchical testing procedure. Safety was analysed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02395172. Enrolment is complete, but the trial is ongoing.Between March 24, 2015, and Jan 23, 2017, 792 patients were enrolled and randomly assigned to receive avelumab (n=396) or docetaxel (n=396). 264 participants in the avelumab group and 265 in the docetaxel group had PD-L1-positive tumours. In patients with PD-L1-positive tumours, median overall survival did not differ significantly between the avelumab and docetaxel groups (11·4 months [95% CI 9·4-13·9] vs 10·3 months [8·5-13·0]; hazard ratio 0·90 [96% CI 0·72-1·12]; one-sided p=0·16). Treatment-related adverse events occurred in 251 (64%) of 393 avelumab-treated patients and 313 (86%) of 365 docetaxel-treated patients, including grade 3-5 events in 39 (10%) and 180 (49%) patients, respectively. The most common grade 3-5 treatment-related adverse events were infusion-related reaction (six patients [2%]) and increased lipase (four [1%]) in the avelumab group and neutropenia (51 [14%]), febrile neutropenia (37 [10%]), and decreased neutrophil counts (36 [10%]) in the docetaxel group. Serious treatment-related adverse events occurred in 34 (9%) patients in the avelumab group and 75 (21%) in the docetaxel group. Treatment-related deaths occurred in four (1%) participants in the avelumab group, two due to interstitial lung disease, one due to acute kidney injury, and one due to a combination of autoimmune myocarditis, acute cardiac failure, and respiratory failure. Treatment-related deaths occurred in 14 (4%) patients in the docetaxel group, three due to pneumonia, and one each due to febrile neutropenia, septic shock, febrile neutropenia with septic shock, acute respiratory failure, cardiovascular insufficiency, renal impairment, leucopenia with mucosal inflammation and pyrexia, infection, neutropenic infection, dehydration, and unknown causes.Compared with docetaxel, avelumab did not improve overall survival in patients with platinum-treated PD-L1-positive NSCLC, but had a favourable safety profile.Merck and Pfizer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
磊4165564发布了新的文献求助10
3秒前
风趣的飞阳完成签到,获得积分10
4秒前
祁琳桐完成签到,获得积分10
5秒前
6秒前
7秒前
Isaac完成签到,获得积分10
7秒前
8秒前
lailailai完成签到,获得积分10
9秒前
香蕉觅云的应助被洁净静竹采纳,获得10
9秒前
隐形曼青的应助被知有采纳,获得10
11秒前
12秒前
juan完成签到 ,获得积分10
12秒前
yu完成签到 ,获得积分0
13秒前
123456完成签到 ,获得积分10
14秒前
TOM完成签到 ,获得积分10
14秒前
风吹麦浪的应助被lailailai采纳,获得10
15秒前
16秒前
17秒前
17秒前
lucky发布了新的文献求助100
18秒前
痞老板死磕蟹黄堡完成签到 ,获得积分10
18秒前
朴实的问雁完成签到 ,获得积分10
20秒前
21秒前
洁净静竹发布了新的文献求助10
22秒前
QQ农场提示我菜死了完成签到,获得积分10
23秒前
23秒前
Raim发布了新的文献求助10
23秒前
26秒前
26秒前
彭于晏的应助被高高采纳,获得10
29秒前
zho发布了新的文献求助10
29秒前
Jayson完成签到,获得积分10
30秒前
ding的应助被知有采纳,获得10
30秒前
666完成签到 ,获得积分10
30秒前
郑朗逸完成签到,获得积分10
30秒前
31秒前
lsyjflstv关注了科研通微信公众号
33秒前
放松完成签到 ,获得积分10
33秒前
飘逸的听露完成签到 ,获得积分10
33秒前
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158533
求助须知:如何正确求助?哪些是违规求助? 9554296
关于积分的说明 21718786
捐赠科研通 7747941
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551811
邀请新用户注册赠送积分活动 2471194